Afinitor (everolimus) Tablets
Afinitor is a kinase inhibitor used for the treatment of children and adults with tuberous sclerosis complex who have a brain tumor called subependymal giant-cell astrocytoma.
Novartis Patient Assistance NOW Oncology provides 3 financial assistance programs for patients using Afinitor:
Novartis Oncology Universal Co-pay Program
Eligible patients with private insurance will pay $0 for a 28-day supply of Afinitor, and Novartis pays up to $15,000 per calendar year.
Novartis Patient Assistance Foundation
Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Afinitor for free through the Novartis Patient Assistance Foundation. To be eligible for financial assistance, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Afinitor for free until prescription drug coverage becomes available to them.
Avastin (bevacizumab) Injection
Avastin is a VEGF-specific angiogenesis inhibitor used for the treatment of patients with recurring glioblastoma, a fast-growing type of brain cancer. Avastin is used as a single agent for adults with progressive disease.
Genentech Oncology provides 2 financial assistance programs for patients using Avastin:
Genentech Oncology Co-pay Assistance Program
Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.
Genentech Patient Foundation
This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.
Danyelza (naxitamab-gqgk) Injection
Danyelza is a GD2-binding monoclonal antibody (an immunotherapy) used for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), of patients aged 1 year or older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have had a partial or minor response to previous therapy or have stable disease.
Y-mAbs Connect offers 2 financial assistance programs for patients using Danyelza:
Y-mAbs Connect Co-pay Program
Eligible patients who have private insurance may have their out-of-pocket costs of Danyelza reduced to $0 with a maximum program benefit of $15,000 per enrollment period.
Y-mAbs Connect Patient Assistance Program
Eligible patients who are uninsured or underinsured may be able to receive Danyelza at no cost through this program.
Gleostine (lomustine)
Gleostine is an alkylating drug used to treat patients with primary and metastatic brain tumors after appropriate surgery and/or radiotherapy.
NextSource Biotechnology provides 1 financial assistance program for patients using Gleostine:
NextSource Cares Patient Assistance Program
This program provides assistance related to coverage, prior authorization, and copay for Gleostine for patients whose total gross yearly household income is equal to or less than 4 times the federal poverty level.
Gliadel Wafer (carmustine implant)
Gliadel Wafer is used for the treatment of patients with newly diagnosed high-grade malignant glioma, a type of brain cancer, in addition to surgery and radiation, and for patients with recurrent glioblastoma multiforme (fast-growing brain cancer), in addition to surgery.
Arbor Pharmaceuticals offers 1 financial assistance program for patients using Gliadel Wafer:
Arbor Patient Assistance Program
The Arbor Patient Assistance Program offers financial assistance for patients using Gliadel Wafer. For patients without insurance whose household income is 200% or less of the federal poverty guideline, Gliadel Wafer may be provided at no cost for patients receiving treatment as inpatients.
Mvasi (bevacizumab-awwb)
Mvasi, a biosimilar to Avastin (bevacizumab), is a VEGF inhibitor used for the treatment of adults with recurrent glioblastoma, a fast-growing type of brain cancer.
Amgen Assist 360 offers 2 financial assistance programs for patients who have been prescribed Mvasi:
Amgen FIRST STEP Program
With this program, eligible patients who have private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.
Amgen Safety Net Foundation
Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements may receive Mvasi for free.
Welireg (belzutifan) Tablets
Welireg a hypoxia-inducible factor inhibitor for adults with von Hippel-Lindau disease and central nervous system hemangioblastomas.
Merck Access Program offers 2 financial assistance programs for patients using Welireg:
Merck Co-Pay Coupon
Eligible patients who have private insurance may pay as little as $5 for the first out-of-pocket cost of Welireg, with a maximum program savings of up to $8,700 per patient. The coupon is valid for up to a 90-day supply per prescription fill, and may be redeemed only once every 21 days.
Merck Patient Assistance Program
Uninsured or underinsured patients may receive Welireg for free through this program. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for couples, or $132,000 or less for a family of 4.
Zirabev (bevacizumab-bvzr)
Zirabev, a biosimilar to Avastin, is a VEGF inhibitor used for the treatment of adults with recurrent glioblastoma, a fast-growing type of brain cancer.
Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Zirabev:
Pfizer Oncology Together Co-Pay Savings Program
This program assists eligible patients with private insurance so that their monthly copay for Zirabev is $0, with a maximum annual benefit of $25,000.
Pfizer Patient Assistance Program
Through this program, patients who are uninsured may qualify to receive Zirabev for free or at a savings. Eligible patients with government insurance may also receive Zirabev for free if they cannot find independent charitable foundation support.
Sandostatin LAR Depot (octreotide acetate) for injectable suspension
Sandostatin LAR Depot is a somatostatin analog used for the treatment of patients with acromegaly who have had a response to and have tolerated Sandostatin subcutaneous injection.
Novartis Patient Assistance NOW Oncology provides 2 financial assistance programs for patients using Sandostatin LAR Depot:
Novartis Oncology Universal Co-pay Program
Eligible patients with private insurance will pay up to $25 per month in copay and co-insurance. The program pays the remaining balance for Sandostatin LAR Depot until a yearly maximum of $15,000 is met.
Novartis Patient Assistance Foundation
Patients who are experiencing financial hardship and have limited or no public or private prescription drug coverage may be eligible to receive Sandostatin LAR Depot for free through the Novartis Patient Assistance Foundation. To be eligible for financial assistance, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Sandostatin LAR Depot for free until a prescription drug coverage becomes available to them.
Somatuline Depot (lanreotide) Injection
Somatuline Depot is a somatostatin analog used for longterm treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy.
IPSEN CARES provides 2 financial assistance programs for patients using Somatuline Depot:
Somatuline Depot Copay Assistance Program
Eligible, privately insured patients pay no more than $5 for Somatuline Depot for 12 months, for 13 injections, or for an annual maximum of $20,000 (whichever comes first). For patients with no insurance or whose insurance does not cover Somatuline Depot, the cost may be more than $5 per prescription, and the maximum benefit amount per prescription is $1,666.66, up to the annual maximum of $20,000 in total.
Somatuline Depot Patient Assistance Program
Eligible patients who are experiencing financial hardship, or have no insurance coverage, and meet specific medical criteria will receive Somatuline Depot for free.
Somavert (pegvisomant)
Somavert is a growth hormone receptor antagonist used for the treatment of patients with acromegaly who have had an inadequate response to surgery or radiation, or for patients who cannot use these therapies.
Pfizer Oncology Together offers 2 financial assistance programs for patients using Somavert:
Somavert Copay/Coinsurance Support Program
Privately insured, eligible patients may pay just a $5 monthly copayment while the card covers copay and co-insurance costs up to $20,000 annually.
Pfizer Bridge Program
This comprehensive reimbursement support service and patient assistance program helps eligible patients access Somavert.
Table. Drugs Prescribed for Brain Cancer & Acromegaly
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Afinitor (everolimus) Tablets
- Novartis
- Treatment of tuberous sclerosis complex with subependymal giant-cell astrocytoma, a type of brain tumor
- Novartis Oncology Universal Co-pay Program
877-577-7756
Free Trial Program
888-923-4648
Novartis Patient Assistance Foundation
800-277-2254
- Avastin (bevacizumab) Injection
- Genentech
- Treatment of glioblastoma
- Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Danyelza (naxitamab-gqgk) Injection
- Y-mAbs Therapeutics
- Treatment, in combination with GM-CSF, of patients aged 1 year or older with relapsed or refractory highrisk neuroblastoma in the bone or bone marrow who have had a partial or minor response to previous therapy or have stable disease
- Y-mAbs Connect
Co-pay Program
833-339-6227
Y-mAbs Connect Patient Assistance Program
833-339-6227
- Gleostine (lomustine)
- NextSource Biotechnology
- Primary and metastatic brain tumor
- NextSource Cares Patient Assistance Program
855-672-2468
- Gliadel Wafer (carmustine implant)
- Arbor Pharmaceuticals
- High-grade malignant glioma
Recurrent glioblastoma multiforme - Arbor Patient Assistance Program
866-516-3950
- Mvasi (bevacizumab-awwb)
- Amgen
- Treatment of recurrent glioblastoma
- Amgen FIRST STEP Program
888-657-8371
Amgen Safety Net Foundation
888-762-6436
- Welireg (belzutifan) Tablets
- Merck
- Treatment of adults with von Hippel-Lindau disease and central nervous system hemangioblastomas
- Merck Co-Pay
Coupon
855-257-3932
Merck Patient Assistance Program
855-257-3932
- Zirabev (bevacizumab-bvzr)
- Pfizer
- Treatment of recurrent glioblastoma in adults
- Pfizer Oncology Together Co-Pay Savings Program
877-744-5675
Pfizer Patient Assistance Program
877-744-5675
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Sandostatin LAR Depot (octreotide acetate) for injectable suspension
- Novartis
- Acromegaly
- Novartis Oncology Universal Co-pay Program
800-577-7756
Novartis Patient Assistance Foundation
800-277-2254
- Somatuline Depot (lanreotide) Injection
- Ipsen
- Acromegaly
- Somatuline Depot Virtual Copay Savings Program
866-435-5677
Somatuline Depot Patient Assistance Program
866-435-5677
- Somavert (pegvisomant)
- Pfizer
- Acromegaly
- Somavert Copay/Coinsurance Support Program
800-645-1280
Pfizer Bridge Program
800-645-1280